APA引文

Mao, Y., Gao, Z., Sun, Y., Shao, C., Duan, H., & Yan, X. (2025, August). Four-year follow-up from the phase 2 study TD-NICE: Neoadjuvant treatment of tislelizumab combined with chemotherapy in resectable esophageal squamous cell carcinoma. BMC Cancer.

Chicago Style (17th ed.) Citation

Mao, Yajie, Zhiyuan Gao, Yichen Sun, Changjian Shao, Hongtao Duan, and Xiaolong Yan. "Four-year Follow-up from the Phase 2 Study TD-NICE: Neoadjuvant Treatment of Tislelizumab Combined with Chemotherapy in Resectable Esophageal Squamous Cell Carcinoma." BMC Cancer Aug. 2025.

MLA引文

Mao, Yajie, et al. "Four-year Follow-up from the Phase 2 Study TD-NICE: Neoadjuvant Treatment of Tislelizumab Combined with Chemotherapy in Resectable Esophageal Squamous Cell Carcinoma." BMC Cancer, Aug. 2025.